Other Oncology — Sales to customers (Note 9)
Johnson & Johnson Other Oncology — Sales to customers (Note 9) increased by 92.0% to $192.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 10.3%, from $214.00M to $192.00M. Over 4 years (FY 2021 to FY 2025), Other Oncology — Sales to customers (Note 9) shows a downward trend with a -3.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration or growth in the secondary oncology product line, while a decrease may signal product maturity, increased competition, or portfolio rationalization.
Detailed definition
This metric represents the total net revenue generated from the sale of oncology pharmaceutical products categorized as...
Peer comparison
Comparable to secondary oncology revenue streams or non-core therapeutic segment sales reported by major pharmaceutical peers.
jnj_segment_other_oncology_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $120.00M | $126.00M | $140.00M | $118.00M | $106.00M | $100.00M | $99.00M | $99.00M | $120.00M | $117.00M | $0.00 | $73.00M | $83.00M | $86.00M | $75.00M | $214.00M | $93.00M | $94.00M | $100.00M | $192.00M |
| QoQ Change | — | +5.0% | +11.1% | -15.7% | -10.2% | -5.7% | -1.0% | +0.0% | +21.2% | -2.5% | -100.0% | — | +13.7% | +3.6% | -12.8% | +185.3% | -56.5% | +1.1% | +6.4% | +92.0% |
| YoY Change | — | — | — | — | -11.7% | -20.6% | -29.3% | -16.1% | +13.2% | +17.0% | -100.0% | -26.3% | -30.8% | -26.5% | — | +193.2% | +12.0% | +9.3% | +33.3% | -10.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's other oncology — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported other oncology — sales to customers (note 9) of $192.00M in Q1 2026.
- How has Johnson & Johnson's other oncology — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's other oncology — sales to customers (note 9) decreased by 10.3% year-over-year, from $214.00M to $192.00M.
- What is the long-term trend for Johnson & Johnson's other oncology — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's other oncology — sales to customers (note 9) has grown at a -3.1% compound annual growth rate (CAGR), from $568.00M to $501.00M.
- What does other oncology — sales to customers (note 9) mean?
- The total net revenue generated from the sale of secondary or niche oncology pharmaceutical products.